News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • A new study led by Dana-Farber researchers shows Venclexta, the first of a new class of drugs that targets cancer cells’ survival proteins, achieved responses in patients with acute myelogenous leukemia (AML) who had relapsed or were resistant to or couldn’t tolerate chemotherapy.

Tags: Leukemia

  • Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study from Dana-Farber researchers found.

Tags: Disparities

  • Dana-Farber Cancer Institute has monetized a portion of its interest in royalties defined by certain licensing agreements related to its Programmed Death Ligand-1 (PD-L1) intellectual property.

Tags: Funding, Immunotherapy

  • Dana-Farber/Brigham and Women’s Cancer Center has been named the best for cancer care in New England for the 16th straight year, and fourth overall in the country by U.S. News & World Report.

Tags: Honors

  • The Stamford Hospital Carl & Dorothy Bennett Cancer Center is the newest member of the Dana-Farber/Brigham and Women’s Cancer Care Collaborative (DF/BWCCC), and the first in Connecticut, Dana-Farber Cancer Institute and Brigham and Women’s Hospital announced today. Participation in the collaborative reflects the Bennett Cancer Center’s demonstrated commitment to excellence by meeting a wide array of standards and best practices.

Tags: Partnerships

  • Dana-Farber Cancer Institute study published in the New England Journal of Medicine suggests that using repeated doses of an immunotherapy drug can restore a complete remission for some relapsed stem cell transplant recipients.

Tags: Leukemia, Lymphoma, Immunotherapy

  • Investigators at Dana-Farber have identified a natural molecular pathway that enables cells to burn off calories as heat rather than store them as fat.

Tags: BasicResearch

  • For the third year in a row, U.S. News & World Report named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #1 pediatric cancer program in its new 2016-17 Best Children's Hospitals rankings.

Tags: ChildhoodCancer, Honors

  • Researchers find cytoreductive nephrectomy may offer an overall survival benefit to patients with metastatic kidney cancer who are treated with targeted therapies.

Tags: Surgery, TargetedTherapy

  • The Harvard Stem Cell Institute (HSCI), three of Harvard’s clinical affiliates, including Dana-Farber Cancer Institute (DFCI), and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.

Tags: BasicResearch, StemCellTransplant

Showing 1-10 of 707 items